CN103917558B - 吲哚烷基氨基‑睡茄甾缀合物及其使用方法 - Google Patents

吲哚烷基氨基‑睡茄甾缀合物及其使用方法 Download PDF

Info

Publication number
CN103917558B
CN103917558B CN201280053772.0A CN201280053772A CN103917558B CN 103917558 B CN103917558 B CN 103917558B CN 201280053772 A CN201280053772 A CN 201280053772A CN 103917558 B CN103917558 B CN 103917558B
Authority
CN
China
Prior art keywords
compound
hydrogen
formula
extract
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280053772.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103917558A (zh
Inventor
希布纳斯·高萨尔
穆鲁加南达姆·韦拉拉格温
桑耶西·R·卡利丁迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natreon Inc
Original Assignee
Natreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natreon Inc filed Critical Natreon Inc
Publication of CN103917558A publication Critical patent/CN103917558A/zh
Application granted granted Critical
Publication of CN103917558B publication Critical patent/CN103917558B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201280053772.0A 2011-11-07 2012-11-06 吲哚烷基氨基‑睡茄甾缀合物及其使用方法 Expired - Fee Related CN103917558B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161556603P 2011-11-07 2011-11-07
US61/556,603 2011-11-07
US13/669,207 US9084800B2 (en) 2011-11-07 2012-11-05 Indolealkylamino-withasteroid conjugates and method of use
US13/669,207 2012-11-05
PCT/US2012/063727 WO2013070619A1 (en) 2011-11-07 2012-11-06 Indolealkylamino-withasteroid conjugates and method of use

Publications (2)

Publication Number Publication Date
CN103917558A CN103917558A (zh) 2014-07-09
CN103917558B true CN103917558B (zh) 2017-04-12

Family

ID=48223848

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280053772.0A Expired - Fee Related CN103917558B (zh) 2011-11-07 2012-11-06 吲哚烷基氨基‑睡茄甾缀合物及其使用方法

Country Status (7)

Country Link
US (2) US9084800B2 (https=)
EP (1) EP2776462B1 (https=)
JP (1) JP6144688B2 (https=)
CN (1) CN103917558B (https=)
BR (1) BR112014010868B1 (https=)
CA (1) CA2854631C (https=)
WO (1) WO2013070619A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503990A (zh) * 2015-12-29 2016-04-20 吴金凤 一种新的睡加内酯类化合物及其制备方法和医药用途
EP3585400B1 (en) * 2017-02-27 2024-11-06 University of Pittsburgh - Of the Commonwealth System of Higher Education Anti-psychotic composition and treatment methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403851A (en) * 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
EP2260855A1 (en) * 2008-03-06 2010-12-15 National Institute of Advanced Industrial Science and Technology Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494698A1 (fr) * 1980-11-21 1982-05-28 Roussel Uclaf Nouveaux derives steroides 3-amino substitues, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
US6153198A (en) * 1999-07-13 2000-11-28 Natreon Inc. Withania somnifera composition
WO2003001881A2 (en) * 2001-06-26 2003-01-09 New York State Office Of Mental Health Cell-based high-throughput screening methods
US6713092B1 (en) 2002-12-03 2004-03-30 Natreon Inc. Withania Somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof
US20050266100A1 (en) * 2004-03-30 2005-12-01 Council Of Scientific And Industrial Research Rafi Marg Process isolation of withaferin-A from plant materials and products therefrom
US20070036873A1 (en) * 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
CA2658959A1 (en) 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
US20110230551A1 (en) 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403851A (en) * 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
EP2260855A1 (en) * 2008-03-06 2010-12-15 National Institute of Advanced Industrial Science and Technology Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Selective Reactivity of 2-mercaptoethanol with 5B,6B-epoxide in steroids from Withania somnifer;Misra Laxminarain等;《Steroids》;20081231;第73卷(第3期);245-251 *

Also Published As

Publication number Publication date
EP2776462A4 (en) 2015-04-08
CA2854631C (en) 2018-12-11
EP2776462B1 (en) 2018-01-10
US20150320771A1 (en) 2015-11-12
US20130115316A1 (en) 2013-05-09
BR112014010868B1 (pt) 2021-07-06
BR112014010868A8 (pt) 2020-04-22
WO2013070619A8 (en) 2014-05-08
WO2013070619A1 (en) 2013-05-16
CA2854631A1 (en) 2013-05-16
CN103917558A (zh) 2014-07-09
JP2015501787A (ja) 2015-01-19
US9084800B2 (en) 2015-07-21
US10449206B2 (en) 2019-10-22
BR112014010868A2 (pt) 2017-06-13
JP6144688B2 (ja) 2017-06-07
EP2776462A1 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
US12280030B2 (en) Method of using a chlorogenic acid composition for supporting cognitive function
CA2378396C (en) Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement
CN103917558B (zh) 吲哚烷基氨基‑睡茄甾缀合物及其使用方法
EP3639817B1 (en) Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases
Ferdous et al. Anticholinesterase and antioxidant activity of Drynaria quercifolia and its ameliorative effect in scopolamine-induced memory impairment in mice
Rodrigues et al. Antinociceptive effect of crude extract, fractions and three alkaloids obtained from fruits of Piper tuberculatum
US8513203B2 (en) Composition and method thereof
KR20090128957A (ko) 두충 껍질 추출물을 이용한 고혈압 예방 음료 및 그제조방법
JP2024105312A (ja) ナツメ属植物及びガラナの生物活性植物化学物質
CN113461702B (zh) 酰基间苯三酚低聚体其制备方法和应用
CN101242828B (zh) 抑制酰基辅酶a：胆固醇酰基转移酶的组合物
KR101055920B1 (ko) 탱자로부터 분리한 8-메톡시소랄렌을 포함하는 알츠하이머 병 예방 또는 치료용 조성물 및 상기 화합물의 분리방법
Ali et al. Anti-Atherosclerosis and Anti-Hypertensive Effects of Flavonoid Isorhamnetin Isolated from the Bark of Cordia dichotoma L
Munira et al. Evaluation of analgesic, anti-inflammatory and CNS depression activities of the methanolic extract of Acacia nilotica seed
Onoja et al. Acetylcholinesterase inhibition and metal chelatin g potentials of fractions and compounds isolated from Cola hispida., 10
Venkatesh et al. Effect of Piperine on Antihyperlipidemic Activity and Pharmacokinetic Profile of Simvastatin
Acero et al. Cholinesterase Inhibitory Activities and In Silico Docking Studies of Blumeatin Isolated from Blumea balsamifera L. DC.
Emmanuel et al. Anti-convulsivant and sedative like-effect of Abyssinone V-4’methyl ether Isolated from Erythrina droogmansiana (Leguminosae)
KR100615357B1 (ko) 인지력 향상효과를 갖는 신규 알칼로이드 유도체 화합물및 이를 함유하는 조성물
KR20240164685A (ko) 뱀톱 추출물 또는 이로부터 분리한 화합물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 조성물
JP2008516992A (ja) エリスリナ・ムルング（Ｅｒｙｔｈｒｉｎａｍｕｌｕｎｇｕ）の含水アルコール抽出物、薬剤組成物及びこれらの物質の生成方法
KR20100002634A (ko) 비만 치료 및 예방용 조성물과 기능성 식품
WO2013179309A1 (en) Novel compounds as memory enhancers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170412

CF01 Termination of patent right due to non-payment of annual fee